In proceedings concerning Highly Innovative Medicinal
Products (VILP), the Institute concluded that no publications are currently
available that would sufficiently demonstrate comparable efficacy in terms of
the parameter of objective response rate (ORR). On this basis, it did not
reduce the reimbursement amount pursuant to Section 39d(9) of the Act on Public
Health Insurance to the level of...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
